Journal
MAYO CLINIC PROCEEDINGS
Volume 87, Issue 9, Pages 879-889Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2012.05.019
Keywords
-
Categories
Funding
- Eisai
- Epilepsy Therapy Project
- MAP
- National Institutes of Health
- Neuropace
- UCB
- Upsher Smith
- Vertex
Ask authors/readers for more resources
There are now 24 antiepileptic drugs (AEDs) approved for use in epilepsy in the United States by the Food and Drug Administration. A literature search was conducted using PubMed, MEDLINE, and Google for all English-language articles that discuss newly approved AEDs and the use of AEDs in epilepsy in the United States from January 1, 2008, through December 31, 2011. Five new agents were identified that have come onto the market within the past 2 years. Moreover, 3 trends involving AEDs have become clinically important and must be considered by all who treat patients with epilepsy. These trends include issues of generic substitution of AEDs, pharmacogenomics predicting serious adverse events in certain ethnic populations, and the issue of the suicide risk involving the entire class of AEDs. This article disdisses the most recent AEDs approved for use in the United States and the 3 important trends shaping the modern medical management of epilepsy. (C) 2012 Mayo Foundation for Medical Education and Research rectangle Mayo Clin Proc. 2012;87(9):879-889
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available